Edwards Lifesciences (NYSE:EW) VP Daniel Lippis Sells 619 Shares of Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 619 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $87.51, for a total value of $54,168.69. Following the completion of the sale, the vice president directly owned 40,034 shares of the company’s stock, valued at $3,503,375.34. This represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Edwards Lifesciences Price Performance

NYSE EW traded down $2.23 during mid-day trading on Friday, hitting $84.54. The stock had a trading volume of 3,795,187 shares, compared to its average volume of 2,600,847. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29. The company has a market cap of $48.68 billion, a price-to-earnings ratio of 48.59, a P/E/G ratio of 2.28 and a beta of 0.85. The company has a 50 day simple moving average of $89.16 and a 200 day simple moving average of $85.79. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.Edwards Lifesciences’s revenue was up 13.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on EW shares. UBS Group began coverage on shares of Edwards Lifesciences in a research report on Tuesday, July 28th. They set a “buy” rating and a $110.00 price target for the company. Wall Street Zen cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Citigroup upped their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Leerink Partners upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $87.00 to $101.00 in a research report on Friday, July 24th. Finally, JPMorgan Chase & Co. raised their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research note on Friday, July 24th. Seventeen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences News Summary

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: CMS expands TAVR coverage: The Centers for Medicare and Medicaid Services will extend Medicare coverage to certain patients with severe aortic stenosis who do not yet have symptoms. The broader eligible patient population could increase demand for Edwards’ TAVR valves and procedures, a particularly important growth opportunity for the company. CMS expands TAVR Medicare coverage to asymptomatic patients
• Positive Sentiment: Company welcomes the policy: Edwards said the national coverage determination should improve patient access to TAVR while reinforcing the role of multidisciplinary Heart Teams. The company also reaffirmed its 2026 financial guidance following the decision, suggesting no immediate deterioration in its outlook. Edwards Lifesciences Reaffirms 2026 Guidance Following Medicare TAVR Decision
• Positive Sentiment: Analysts remain bullish: Citi initiated or reiterated a Buy view, while BTIG reaffirmed its Buy rating with a $110 price target. William Blair also maintained a Buy rating, citing the expanded TAVR coverage and inclusion of asymptomatic patients. These targets imply substantial potential upside from recent trading levels. Analyst Buy Rating on Edwards Lifesciences
• Neutral Sentiment: Why the stock may still be under pressure: The reports identify no new company-specific negative catalyst. Investors may be waiting for evidence that the CMS change translates into procedure volumes and revenue, while Edwards’ relatively elevated valuation—about 49 times earnings—could make the shares sensitive to profit-taking or broader market weakness.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in EW. BlackRock Inc. purchased a new stake in shares of Edwards Lifesciences in the second quarter valued at $5,318,092,000. Varma Mutual Pension Insurance Co purchased a new position in shares of Edwards Lifesciences during the second quarter valued at $11,168,000. Norges Bank acquired a new position in Edwards Lifesciences during the fourth quarter valued at $803,686,000. Conway Capital Management Inc. acquired a new position in Edwards Lifesciences during the second quarter valued at $954,000. Finally, TD Asset Management Inc lifted its stake in Edwards Lifesciences by 6.4% in the 4th quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company’s stock worth $66,335,000 after acquiring an additional 47,051 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company’s portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.